Molecular Diagnostics Veteran Heiner Dreismann, Ph.D., Joins PDI, Inc. Board of Directors

 Molecular Diagnostics Veteran Heiner Dreismann, Ph.D., Joins PDI, Inc. Board
                                 of Directors

PR Newswire

PARSIPPANY, N.J., Aug. 13, 2014

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ --PDI, Inc. (Nasdaq: PDII), a
leading healthcare commercialization company, today announced that Heiner
Dreismann, Ph.D., former president and chief executive officer of Roche
Molecular Systems, Inc., has joined its board of directors. Effective
immediately, his addition brings the total number of board members to seven.

Diagnostics industry veteran, Heiner Dreismann, Ph.D., former President and
CEO of Roche Medical Systems has joined the Board of Directors for PDI, Inc.

Dr. Dreismann possesses more than 27 years of global diagnostics experience in
various positions at Roche Diagnostics and later Roche Molecular Systems
(RMS), a business unit of Roche Diagnostics. In his last role at RMS,
Dreismann oversaw the doubling of the molecular in vitro diagnostics business
to over $1 billion and had overall responsibilities for business, corporate
and R&D functions, as well as the respective staff.

"Dr. Dreismann has been on the cutting edge of the molecular diagnostics
industry for his entire career, and his experience will be invaluable as a
member of PDI's board of directors," said Jerry Belle, Chairman of the Board,
PDI, Inc. "Dr. Dreismann's extensive industry and technical knowledge,
business acumen and ability to effect change perfectly aligns with our long
term vision and strategy for PDI."

Dr. Dreismann also serves on the boards of directors of several other public
and privately held companies, including GeneNews, Stratos Genomics, Magellan
Diagnostics, Singulex, Celula, Inc. and Myriad Genetics, among others.

"I am honored at this election to PDI's board and look forward to contributing
my insight and perspectives as a member," said Dreismann. "The company is
truly evolving as an innovative healthcare company and as a
commercially-oriented molecular diagnostics company. I eagerly anticipate
playing a role in helping to further its progress."

Dr. Dreismann received his Ph.D. (summa cum laude) in Microbiology/Molecular
Biology and Master's degree in Biology from Westfaelische Wilhelms University,
Muenster, and completed a Post-Doctoral Fellowship at the French Center for
Nuclear Research in Saclay. He is a current member of the European Diagnostic
Manufacturers Association, the American Society for Microbiology and New York
Academy of Sciences.

About PDI, Inc.

PDI is a leading healthcare commercialization company providing superior
go-to-market strategy and execution to established and emerging healthcare
companies through its three core business units. PDI's Interpace Diagnostics
subsidiary is working to develop and commercialize molecular diagnostic tests
leveraging the latest technology and personalized medicine for better patient
diagnosis and management. The company's Contract Sales business unit (CSO) is
a leading provider of outsourced pharmaceutical, medical device and
diagnostics sales teams. Its Group DCA division is a pioneer in insight-driven
digital communication services and integrated multichannel message delivery.

For more information about PDI, Inc. or Interpace Diagnostics, please visit and

Forward-Looking Statements
This press release contains forward-looking statements regarding future events
and financial performance. These statements are based on current expectations
and assumptions involving judgments about, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which
are beyond PDI's control. These statements also involve known and unknown
risks, uncertainties and other factors that may cause PDI's actual results to
be materially different from those expressed or implied by any forward-looking
statement. For example, with respect to statements regarding projections of
future revenues, growth and profitability, estimated gross profit and
anticipated internal rate of return on investments actual results may differ
materially from those set forth in this release based on the loss, early
termination or significant reduction of any of our existing service contracts,
the failure to meet performance goals in PDI's incentive-based arrangements
with customers, the inability to secure additional business or our inability
to develop more predictable, higher margin business through in-licensing or
other means. Additionally, all forward-looking statements are subject to the
risk factors detailed from time to time in PDI's periodic filings with the
Securities and Exchange Commission, including without limitation, PDI's
previously filed Annual Report on Form 10-K for the year ended December 31,
2013 and current reports on Forms 10-Q and Forms 8-K. Because of these and
other risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these statements
speak only as of the date of this press release and, except as may be required
by law, PDI undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.

PDI is a leading health care commercialization company providing superior
insight-driven, integrated multi-channel message delivery to established and
emerging health care companies. The company is dedicated to enhancing
engagement with health care practitioners and optimizing commercial
investments for its clients by providing strategic flexibility, full product
commercialization services, innovative multi-channel promotional solutions,
and sales and marketing expertise.

Photo -
Logo -


Contact: Media: Caren Begun, Green Room Communications, (856) 424-2023,; Investors: Asher Dewhurst, Westwicke Partners, (443)
Press spacebar to pause and continue. Press esc to stop.